Docetaxel (Taxotere®) in combination chemotherapy and in association with thoracic radiotherapy for the treatment of non-small-cell lung cancer

Annals of Oncology

Volumn 10, Issue SUPPL. 5, 1999, Pages

  Ornstein, D L ^b   Nervi, A M ^b   Rigas, J R ^a  

^a Thoracic Oncology Program   (United States)

^b NONE

Author keywords

Lung cancer; Radiotherapy; Taxotere

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; PACLITAXEL; TAXOID; VINBLASTINE;

ADULT; AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; SURVIVAL TIME; TREATMENT OUTCOME; LUNG TUMOR; MULTIMODALITY CANCER THERAPY; REVIEW; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; HUMANS; LUNG NEOPLASMS; PACLITAXEL; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME; VINBLASTINE;

EID: 0032692490     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/10.suppl_5.S35     Document Type: Conference Paper

References (36)

1. Burris H, Eckardt J, Fields S et al. Phase II trials of taxotere in patients with non-small-cell lung cancer. Proc Am Soc Clin Oncol 1993; 12: 335.
2. Cerny T, Kaplan S, Pavlidis N et al. Docetaxel (Taxotere) is active in non-small-cell lung cancer: A phase II trial of the EORTC Early Clinical Trials Group (ECTG) (see comments). Br J Cancer 1994; 70 (2): 384-7.
3. Fossella FV, Lee JS, Murphy WK et al. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 1994; 12 (6): 1238-44.
4. Francis PA, Rigas JR, Kris MG et al. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 1994; 12 (6): 1232-7.
5. Rigas JR. Single-agent docetaxel in previously untreated non-small-cell lung cancer. Oncology 1997; 11 (7, Suppl 7): 17-21.
6. Gandara D, Vokes E, Green M et al. Docetaxel (Taxotere) in platinum-treated non-small-cell lung cancer (NSCLC): Confirmation of prolonged survival in a multicenter trial. Proc Am Soc Clin Oncol 1997; 16: 454a.
7. Le Chevalier T, Brisgand D, Douillard JY et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12: 360-7.
8. Crawford J, O'Rourke M, Schiller JH et al. Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. J Clin Oncol 1996; 14: 2774-84.
9. Van Moorsel CJA, Peters GJ, Pinedo HM. Gemcitabine: Future prospects of single-agent and combination studies. Oncologist 1997; 2: 127-34.
10. Kris M, Cohen E, Gralla R. An analysis of 134 phase II trials in NSCLC. Toronto: Proc IV World Conference Lung Cancer 1985.
11. Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 1997; 48: 353-74.
12. Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a Taxol analogue. Cancer Res 1991; 51: 4845-52.
13. Bissery M, Vrignaud P, Baysass M et al. Preclinical in vivo activity of docetaxel-containing combinations. Proc Am Soc Clin Oncol 1995; 14: 489.
14. Millward MJ, Zalcberg J, Bishop JF et al. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 1997; 15 (2): 750-8.
15. Pronk L, Schellens J, Planting A et al. Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors. J Clin Oncol 1997; 15: 1071-91.
16. Belani C, Bonomi P, Dobbs T et al. Multicenter phase II trial of docetaxel and cisplatin combination in patients with non-small-cell lung cancer. Proc Am Soc Clin Oncol 1997: 462a.
17. Cole J, Gralla R, Marques C, Rittenberg C. Phase I-II study of cisplatin + docetaxel (Taxotere) in non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1995; 14: 357.
18. Douillard J, Monnier A, Ibrahim N et al. Preliminary report of a phase II study of docetaxel (Taxotere) and cisplatin in advanced non-small-cell lung cancer (NSCLC). Eur J Cancer 1995; 31A (Suppl 5): S228.
19. Androulakis N, Dimopoulos A, Kourousis et al. First-line treatment of advanced non-small-cell lung cancer (NSCLC) with docetaxel and cisplatin: A multicenter phase II study. Proc Am Soc Clin Oncol 1997; 16: 461a.
20. Belani CP. Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer. Oncology (Huntingt) 1997; 11 (8, Suppl 8): 42-5.
21. Mattson K, Saarinen A, Jekunen A. Combination treatment with docetaxel (Taxotere) and platinum compounds for non-small-cell lung cancer. Semin Oncol 1997; 24 (4, Suppl 14): 5-8.
22. Viallet J, Laberge F, Martins H et al. Docetaxel alternating with cisplatin and vinorelbine: Early evidence of additive activity in a phase II trial of non-small-cell lung cancer. Proc Am Soc Clin Oncol 1996; 15: 375.
23. Orcel B. Antoine E, Benhammouda A et al. Sequential administration of docetaxel followed by cisplatin-vindesine in chemotherapy-naïve patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1997; 16: 477a.
24. Belani C, Hadeed V, Ramanathan R et al. Docetaxel and carboplatin: A phase I and pharmacokinetic trial for advanced non-hematologic malignancies. Proc Am Soc Clin Oncol 1997; 16: 220a.
25. Douillard J, Monnier A, Chevalier TL et al. Docetaxel in combination with vinorelbine in chemotherapy-naïve patients with metastatic or unresectable non-small-cell lung cancer (NSCLC): Preliminary results of a phase I study. Lung Cancer 1997; 18 (Suppl 1): 58 (Abstr 223).
26. Early E, Miller V, Grant S et al. Phase I-II trial of docetaxel and vinorelbine with filgrastim (G-CSF) in patients with advanced non-small-cell lung cancer. Proc Soc Clin Oncol 1997; 16: 467a.
27. Schiller J, Larson M, Larson M, Pharo L. Phase I trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy. Proc Am Soc Clin Oncol 1997; 16: 481a.
28. Trillet-Lenoir V, Monnier A, Douillard J et al. Interim results of a phase II study of docetaxel (Taxotere) and vinorelbine in chemotherapy-naïve patients with advanced non-small-cell lung carcinoma. Ann Oncol 1996; 7 (Suppl 5): 95.
29. Kourousis C, Kakolyris S, Androulakis N et al. First-line treatment of non-small-cell lung carcinoma with docetaxel and vinorelbine: A phase II study. Proc Am Soc Clin Oncol 1996; 16: 405.
30. Georgoulias V, Kourousis C, Androulakis N et al. Docetaxel (Taxotere) and gemcitabine in the treatment of non-small-cell lung cancer: Preliminary results. Semin Oncol 1997; 24 (4, Suppl 14): 22-5.
31. Dillman R, Seargren S, Propert K et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990; 323: 940-5.
32. Hei TK, Piao CQ, Geard CR, Hall EJ. Taxol and ionizing radiation: Interaction and mechanisms. Int J Radiat Oncol Biol Phys 1994; 29 (2): 267-71.
33. Hennequin C, Giocanti N, Favaudon V. Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Cancer Res 1996; 56 (8): 1842-50.
34. Aamdal S, Wibe E, Hallen M et al. Phase I study of concomitant docetaxel (Taxotere) and radiation in locally advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1997; 16: 460a.
35. Mauer AM, Masters GA, Haraf DJ et al. Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol 1998; 16 (1): 159-64.
36. Koukourakis M, Kourousis C, Androulakis N et al. Accelerated radiotherapy and weekly docetaxel for non-small-cell lung cancer: A dose escalation phase I-II study. Proc Am Soc Clin Oncol 1997; 16: 472a.